Premium
Topical treatment with 0.05% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis
Author(s) -
KONTADAKIS G,
PLAKA A,
LIMNOPOULOU A,
DIAKONIS V,
KYMIONIS G
Publication year - 2011
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2011.410.x
Subject(s) - medicine , vernal keratoconjunctivitis , visual acuity , keratoconjunctivitis , treatment modality , surgery , dermatology , ophthalmology
Purpose To evaluate the treatment with topical 0,05% cyclosporine A (CsA) in patients with subepithelial corneal infiltrates secondary to adenoviral keratoconjunctivitis. Methods 4 patients (8 eyes) before and after treatment with CsA 0.05% eyedrops twice daily were prospectively examined. All patients had been treated with topical corticosteroids previously without improvement. The objective data recorded included best‐corrected decimal visual acuity, intraocular pressure and evaluation of severity of SEIs (improved, stable, or worse). Results 1 male and 3 females, mean age of 45 +/‐ 10 years, were included. Mean follow‐up on CsA was 12 months +/‐ 4 months. The mean best‐corrected decimal visual acuity before and after treatment was 0.8 +/‐ 0.25 and 1.0 +/‐ 0.28, respectively. 3 patients showed clinical improvement, and 1 was stable during the treatment period. Patients reported reduction in the severity of symptoms before and after the treatment. Most of the patients reported no foreign body sensation, glare, or other side effects with topical CsA treatment. Overall, patients noted an improvement in vision and satisfaction with CsA treatment. Conclusion Topical CsA 0.05% is a safe and effective alternative treatment in patients with SEIs who do not respond to other treatment modalities or have unwanted side effects from topical steroids.